Salt pills for heart failure? new study investigates
NCT ID NCT07614295
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding a small amount of salt (3 grams daily) to the diet can help people with chronic heart failure who have low blood sodium levels. Researchers will compare salt pills to a placebo in 30 adults over three months. The goal is to see if salt improves how the body handles sodium, blood pressure, and hormone activity, while also checking for safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Chronic heart failure NYHA I-III. 2. LVEF ≤40% documented in the echocardiography. 3. Stable Heart Failure symptoms: * Stable symptoms (subjectively declared by the patient) over the past three months. * No increase in peripheral edema or body weight (declared by the patient). * Loop diuretic dose equivalent to 80 mg of furosemide or 20 mg of torasemide daily, with no changes in the past three months. 4. Age over 18 and under 85 years. 5. Male or female. 6. Use of guideline-directed medical therapy (GDMT), with each drug group at maximum tolerated doses but no more than half of the maximum dose. 7. Systolic blood pressure \<100 mmHg and/or diastolic blood pressure \<60 mmHg. 8. Resting heart rate up to 80 bpm. 9. Serum sodium concentration \<140 mmol/L, regardless of the cause. Exclusion Criteria: 1. Hospitalization due to heart failure decompensation within the last three months. 2. Primary hypertrophic or restrictive cardiomyopathy, constrictive pericarditis. 3. Systemic disease known to be associated with cardiac muscle infiltration. 4. Significant valvular disease (moderate or severe stenosis of any valve, moderate or severe aortic or pulmonary regurgitation, severe tricuspid or mitral regurgitation). 5. Severe renal impairment (eGFR \<30 mL/min/1.73 m² based on the MDRD formula). 6. Stroke or transient ischemic attack (TIA) within the last three months. 7. Cardiac resynchronization therapy (CRT), ICD, ablation, or pacemaker implantation (or planned implantation) within the last three months. 8. Severe lung disease or "cor pulmonale" or other causes of isolated right ventricular failure not associated with left ventricular dysfunction. 9. Severe lung disease with respiratory failure requiring home oxygen therapy. 10. Body weight \<40 kg or ≥150 kg. 11. Life expectancy \<12 months according to the investigator's assessment 12. Pregnancy or breastfeeding. 13. Ongoing drug or alcohol abuse. 14. Lactose intolerance.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic heart failure with reduced ejection fraction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institute of Heart Diseases, Wroclaw Medical University
Wroclaw, Lower Silesian Voivodeship, 50-536, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A gentle electric pulse to the heart: new device tested for heart failure
- Heart failure drug puzzle: study aims to untangle polypharmacy risks
- Smartphone app may help heart failure patients get the right meds faster
- Which workout is best for heart failure? new study aims to find out
- Could a common steroid speed heart shock recovery?
- Smart alerts aim to cut heart failure hospital stays